Nausea and vomiting There is some evidence that<unk>  has antiemetic activity. It is recommended by the Canadian Headache Society for treatment of nausea associated with acute migraine. Gastroparesis Gastroparesis is a medical condition characterised by delayed emptying of the stomach when there is no mechanical gastric outlet obstruction. Its cause is most commonly idiopathic, a diabetic complication or a result of abdominal surgery. The condition causes nausea, vomiting, fullness after eating, early satiety (feeling full before the meal is finished), abdominal pain and bloating.<unk>  can be used to increase the transit of food through the stomach by increasing gastrointestinal peristalsis and hence to treat gastroparesis. It may be useful in idiopathic and diabetic gastroparesis. However, increased rate of gastric emptying induced by drugs like<unk>  does not always correlate well with relief of symptoms. Lactation The hormone prolactin stimulates lactation (production of breast milk). Dopamine, released by the hypothalamus stops the release of prolactin from the pituitary gland.<unk> , by acting as an anti-dopaminergic agent, results in increased prolactin secretion, and thus promotes lactation (that is, it is a galactogogue).<unk>  moderately increases the volume of expressed breast milk in mothers of preterm babies where breast milk expression was inadequate, and appears to be safe for short-term use for this purpose. In the United States,<unk>  is not approved for this or any other use. A study called the EMPOWER trial was designed to assess the effectiveness and safety of<unk>  in assisting mothers of preterm babies to supply breast milk for their infants. The study randomized 90 mothers of preterm babies to receive either<unk>  10 mg orally three times daily for 28 days (Group A) or placebo 10 mg orally three times daily for 14 days followed by<unk>  10 mg orally three times daily for 14 days (Group B). Mean milk volumes at the beginning of the intervention were similar between the 2 groups. After the first 14 days, 78% of mothers receiving<unk>  (Group A) achieved a 50% increase in milk volume, while 58% of mothers receiving placebo (Group B) achieved a 50% increase in milk volume. To induce lactation,<unk>  is used at a dosage of 10 to 20 mg 3 or 4 times per day by mouth. Effects may be seen within 24 hours or may not be seen for 3 or 4 days. The maximum effect occurs after 2 or 3 weeks of treatment, and the treatment period generally lasts for 3 to 8 weeks. A 2012 review shows that no studies support prophylactic use of a galactagogue medication at any stage of pregnancy, including<unk> . Other uses Parkinson's disease Parkinson's disease is a chronic neurological condition where a decrease in dopamine in the brain leads to rigidity (stiffness of movement), tremor and other symptoms and signs. Poor gastrointestinal function, nausea and vomiting is a major problem for people with Parkinson's disease because most medications used to treat Parkinson's disease are given by mouth. These medications, such as levodopa, can cause nausea as a side effect. Furthermore, anti-nausea drugs, such as metoclopramide, which do cross the blood–brain barrier may worsen the extrapyramidal symptoms of Parkinson's disease.<unk>  can be used to relieve nausea and gastrointestinal symptoms in Parkinson's disease; it blocks peripheral D2 receptors but minimally crosses the blood–brain barrier in normal doses (the barrier between the blood circulation of the brain and the rest of the body) so has no effect on the extrapyramidal symptoms of the disease. Other gastrointestinal uses<unk>  may be used in functional dyspepsia in both adults and children. It has also been found effective in the treatment of reflux in children. However some specialists consider its risks prohibitory of the treatment of infantile reflux. Available forms<unk>  is available for use by oral administration in the form of tablets, orally disintegrating tablets, and suspension, and by rectal administration in the form of suppositories. The oral tablets are available in the strength of 10 mg.<unk>  has been studied for use by intramuscular injection and an intravenous formulation was previously available, but the medication is now only available in forms for oral and rectal administration.
Domperidone
Primidone
Chlortalidone
Thioridazine
Cinolazepam
Fluparoxan
Mepiprazole
Ziprasidone